Home > Boards > US Listed > Biotechs > Anavex Life Sciences Corp (AVXL)

Yes the trials if taking place in Australia

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Investor2014 Member Profile
 
Followed By 28
Posts 13,427
Boards Moderated 0
Alias Born 11/23/16
160x600 placeholder
Anavex Life Sciences Announces Notice of Allowance for U.S. Patent Application with Expanding Claims Covering ANAVEX®2-73 (b... GlobeNewswire Inc. - 11/30/2020 7:00:00 AM
Anavex Life Sciences to Present at the Evercore ISI 3rd Annual HealthCONx Conference GlobeNewswire Inc. - 11/25/2020 7:00:00 AM
Proof of Concept Controlled Phase 2 Clinical Trial Data Evaluating ANAVEX®2-73 (blarcamesine) in Parkinson’s Disease Demen... GlobeNewswire Inc. - 11/6/2020 10:45:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/15/2020 7:05:29 AM
Anavex Life Sciences Announces Positive Results from Proof of Concept controlled Phase 2 Clinical Trial Evaluating ANAVEX®2-... GlobeNewswire Inc. - 10/15/2020 7:00:10 AM
Anavex Life Sciences Announces Completion of ANAVEX®2-73 (blarcamesine) U.S. Phase 2 Rett Syndrome Clinical Trial GlobeNewswire Inc. - 9/10/2020 7:00:10 AM
Anavex Life Sciences to Present at Upcoming Global Healthcare Conferences GlobeNewswire Inc. - 9/8/2020 7:00:10 AM
Anavex Life Sciences Announces Commitment for Financial Investment by Shake It Up Foundation for Parkinson’s Research for C... GlobeNewswire Inc. - 8/19/2020 7:00:10 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/6/2020 4:11:04 PM
Anavex Life Sciences Reports Fiscal 2020 Third Quarter Financial Results And Provides Business Updates GlobeNewswire Inc. - 8/6/2020 7:00:10 AM
Anavex Life Sciences Receives TGA Special Access Scheme Approval for ANAVEX®2-73 (blarcamesine) for Alzheimer’s Disease Pa... GlobeNewswire Inc. - 8/5/2020 4:05:10 PM
Anavex Life Sciences to Announce Fiscal 2020 Third Quarter Financial Results on Thursday, August 6th, 2020 GlobeNewswire Inc. - 8/4/2020 7:00:10 AM
Anavex Life Sciences Announces First Participant Enrolled in Phase 1 Study of ANAVEX®3-71 (AF710B) GlobeNewswire Inc. - 7/6/2020 7:00:10 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/2/2020 6:26:44 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 7/2/2020 6:25:15 PM
Anavex Life Sciences Announces First Patient Dosed in EXCELLENCE Phase 2/3 Clinical Trial of ANAVEX®2-73 (Blarcamesine) in P... GlobeNewswire Inc. - 7/1/2020 7:00:10 AM
Anavex Life Sciences Announces Exceeding of Enrollment Target for the ANAVEX®2-73 (blarcamesine) U.S. Phase 2 Rett Syndrome ... GlobeNewswire Inc. - 6/16/2020 7:00:10 AM
Anavex Life Sciences Receives Regulatory Approval from Health Canada and UK MHRA Expanding Phase 2b/3 ANAVEX®2-73 (blarcames... GlobeNewswire Inc. - 6/4/2020 7:00:10 AM
Anavex Life Sciences Announces Initiation of First-in-Human Phase 1 Study of ANAVEX®3-71 (AF710B) GlobeNewswire Inc. - 5/21/2020 7:00:10 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/7/2020 4:41:44 PM
Anavex Life Sciences Reports Fiscal 2020 Second Quarter Financial Results And Provides Business Updates GlobeNewswire Inc. - 5/7/2020 7:00:10 AM
Anavex Life Sciences to Announce Fiscal 2020 Second Quarter Financial Results on Thursday, May 7th, 2020 GlobeNewswire Inc. - 5/5/2020 7:00:10 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/1/2020 7:08:41 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 5/1/2020 7:08:14 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 5/1/2020 7:03:26 AM
Investor2014   Wednesday, 10/21/20 07:35:25 AM
Re: McMagyar post# 277543
Post # of 286190 
Yes the trials if taking place in Australia will be cheaper, but the pivotal P3 trials will most likely be conducted out of the U.S. and hence discussions and guidance from the FDA.

Already the AD P2a/3 trial has expanded into Europe and Canada. Although Missling claimed in the quarterly CC that trial cost would not go up as result, I think that is not strictly true. Only technical true, but not with cash tax credit of 43% like in Australia.

Still unlikely to eat too much into the $250M shelf especially if SP ascends on the readouts this year and stabilises higher.

Some additional funding will be required from somewhere, but I suspect Missling won’t take them from any partners until pivotal results are in and valuation is up.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences